Navigation Links
Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
Date:12/1/2008

ngya has three Evaluation Centers: the Drug Clinical Evaluation Center (DCEC), Pharmaceutical Analysis Center (PAC) and Drug Pre-clinical Evaluation Center (DPEC). DCEC mainly cooperates with the third Xiangya Hospital of CSU to conduct Phase I clinical trials for new drugs, and Pharmacokinetics (PK) and Bioequiavailability (BE) studies in other stages of clinical trials. PAC is chiefly responsible for the studies related to pharmaceutical analysis. DPEC is principally in charge of PK screening of compound candidates; PK studies, Pharmacodynamics (PD) studies, quality specification studies, and manufacturing process studies during pre-clinical studies.

Professor Cheng Zeneng, Deputy Dean of the School of Pharmacy of CSU, Director of Drug Metabolism and Pharmacokinetics Research Institute, Deputy Director of Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU, expressed, "CSU and its affiliated hospitals are equipped with high technologies and abundant resources, in complementary, Tigermed has sufficient funds and rich management expertise, so we are quite confident of building up Tigermed Xiangya as a leading Drug Clinical Evaluation Center in China."

"To set up Tigermed Xiangya is a significant move for us to complete our clinical service chain and this union of two titans will tremendously boost Tigermed's serviceability in Phase I clinical trials," comments Ms Cao Xiaochun, Vice President of Tigermed, "We are looking forward to the great future of Tigermed Xiangya, and it will be the first trial and a unique pioneering effort in China's CRO industry".

    For more information, please contact:

     Zeng Haiyan
     Tel:   +86-571-8998-6792
     Email: pr@tigermed.net

'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
2. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
5. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  OncoSec Medical Inc. ("OncoSec") ... intratumoral cancer immunotherapies, today announced a collaboration with ... Veterinary Medicine to test ImmunoPulse™ IL-12 as an ... primary goals of the canine study are to ... of ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
(Date:5/30/2015)... and RARITAN, N.J. ... international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 ... an investigational, human anti-CD38 monoclonal antibody – achieved ... (95% CI, 20.8-38.9), as assessed by an independent ... myeloma. The ORR was consistent among the pre-specified ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7
... for Talent is opening up. Tens of millions of people ... join, or are already in, the workforce - bringing expectations, ... Those organizations that can inspire the passion and harness the ... their competitors. Here's why. , ,Until recently, workers of ...
... note: Janet Dillione is president of the health services ... largest medical technology companies. She has something in common with Donna ... - both recently were named among the Top 25 women in ... are some excerpts from a recent WTN interview with Dillione. ...
... Court has issued several rulings that have eroded the strength ... v. AT&T , the Supreme Court delivered another blow by ... law governs domestically but does not rule the world. , , ... Court addressed Section 271(f) of the patent code, which prohibits a ...
Cached Biology Technology:Media-savvy workers: New front in the War for Talent 2Media-savvy workers: New front in the War for Talent 3Media-savvy workers: New front in the War for Talent 4Media-savvy workers: New front in the War for Talent 5Siemens health services president calls IT benefits unassailable 2Siemens health services president calls IT benefits unassailable 3Siemens health services president calls IT benefits unassailable 4Siemens health services president calls IT benefits unassailable 5Supreme Court limits foreign reach of U.S. patents 2Supreme Court limits foreign reach of U.S. patents 3Supreme Court limits foreign reach of U.S. patents 4
(Date:6/1/2015)... 2015 According to a new ... by Technology (Touch-based & Touchless), Application (Consumer Electronics, Automotive, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... to reach $23.55 Billion by 2020, at a CAGR ... Browse 83 market data T ables and   ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... Jrgen Kjems and Morten Trillingsgaard Ven, Department of Molecular ... contribute to an article on microRNA-128 just published in ... was possible to control the amount of microRNA-128 in ... "If microRNA-128 is kept down in these neurons in ...
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... New York have reported the successful transformation of vegetable ... a structuring agent. The findings portend the development of ... acids, which have been linked to coronary artery disease, ... College Professor of Chemistry George John, tested two sugar ...
Cached Biology News:New research provides insight into epilepsy 2ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3CCNY chemists use sugar-based gelators to solidify vegetable oils 2
... of your microarray data using Asuragens bioinformatics ... from consultation to extensive data analysis using ... our expertise in combination with the Gene ... microarray experiments., ,Normalization and basic statistical analysis ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ...
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
Biology Products: